SIB-IMRT with concomitant chemotherapy-cetuximab after induction chemotherapy for locally-advanced-head-and-neck squamous cell carcinomas

  • Rodriguez-ruiz M
  • López-picazo J
  • Olarte A
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Purpose. To determine tolerability and efficacy of induction chemotherapy (I-CHT) followed by simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) with concurrent chemotherapy/cetuximab (C-CHT) for locally-advanced squamous-head-and-neck carcinoma (LA-SHNC). Methods and materials. Nineteen patients (13M/6F) with LA-SHNC (stage III:3-IV:16) were enrolled in a prospective study between March'07 and September'10, including 6 oral cavity/5 oropharynx/5 hypopharynx/2 larynx/1 paranasal sinuses. Four P16-HPV were identified. Two-cycles of Docetaxel/CDDP/Capecitabine, followed by SIB-IMRT andweekly CDDP/Cetuximabwere prescribed. Staging studies included PET-CT with thermoplastic mask, used for to delimited target volumes. Weekly Cone-beam-IGRT was used. The prescribed SIB-IMRT doses to GTV, CTV and PTV were 73.6 Gy (2.24 Gy/f), 56.2 Gy (1.7 Gy/f) and 51.2 Gy (1.6 Gy/f), respectively, in 30 daily fractions. Survival, patterns of failure and acute/late toxicity were analyzed. Local recurrences were identified on MRI and/or PET/CT, and contoured (V-recur) on the original planning-CT. Local failure was classified according to the location of V-recur respect the 95% isodose line GTV prescription (IDL) as “in-field”, “marginal” and “outside” when >95%, 20-95% or <20% of V-recur was within the 95% IDL, respectively. Data from DVH of target and organs-at-risk volume were analyzed. Results. Eighteen patients received 2-cycles of I-CHT. All patients received the prescribed SIB-IMRT dose, median of C-CHT 6- cycles. After complete treatments, objective response was 95% (79%complete/16%partial). Highest toxicity during I-CHT was grade3-4 (31%). During SIB-IMRT,most frequent grade >3 toxicity wasmucositis/dysphagia (32%). No treatment-related dead was observed. Two osteonecrosis were observed. None other late toxicity grade >2 was observed. After 37 months (18-56) median follow-up, 6 patients (31%) relapsed: 1 distant and 5 local (4 “in fied”/1 “marginal”). Three-year D-DFS, L-DFS, DFS, and OS were 94%, 69%, 54%, and 66%, respectively. Univariate study determinate worse OS in undifferentiated SHNC type (p = 0.028), and no complete response after treatments (p = 0.001). Tumor location was predictor of local control: better in oropharyngeal and laryngeal (p = 0.001). Multivariate analysis showed cervical esophagus V50 > 7% (p = 0.001) as predictor of acute mucositis/dysphagia ≥grade3 (p = 0.005). Conclusion. SIB-IMRT with C-CHT after I-CHT is feasible and well tolerated schedule that shortens the overall treatment time in radical treatment of LA-HNSC, achieving encouraging local and distant control rates. A larger population of patients is needed.

Cite

CITATION STYLE

APA

Rodriguez-ruiz, M., López-picazo, J., Olarte, A., Arbea, L., Alcalde, J., Cambeiro, M., … Moreno-jimenez, M. (2013). SIB-IMRT with concomitant chemotherapy-cetuximab after induction chemotherapy for locally-advanced-head-and-neck squamous cell carcinomas. Reports of Practical Oncology & Radiotherapy, 18, S254. https://doi.org/10.1016/j.rpor.2013.03.286

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free